AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00953641 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
Study NCT01862081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Participants will receive docetaxel 75 milligrams per meter-squared (mg/m\^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
Study NCT00953641 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
Study NCT01862081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0032
Description: Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
Study NCT01862081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel 80 mg/m\^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
Study NCT01519401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mg drospirenone and 20 µg ethinyl-estradiol
Study NCT01519401 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 mg drospirenone and 30 µg ethinyl-estradiol
Study NCT00326222 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: Self-management group education
Study NCT04742049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation-based
Description: 15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. Online exercise training protocol will be apply for patients. Each training protocol was planned as 30 minutes for 3 days a week for 6 weeks with a physiotherapist. Exercise protocol will start with the warm-up exercises and finish with cooling exercises.
Study NCT04742049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up based
Description: 15 pediatric cystic fibrosis patients who are at home during the self- isolation process due to the COVID-19 pandemic will be included in this group. An exercise document including the same exercise protocol in study group will be sent the patients. Patients will be called by the physiotherapist once a week for follow-up. .
Study NCT02003729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Sleep Monitor
Description: ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
Study NCT02325687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture (Standard-of-Care)
Description: All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
Study NCT04173871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protac Myfit®
Description: A systematic proprioceptive-tactile stimulation by the Protac MyFit® vest. The children are asked to wear the Protac Myfit® vest from the beginning of every school day and for at least two sessions for three weeks.
Study NCT01684683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline
Description: Theophylline 0.1 bid
Study NCT01205906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help for tinnitus
Description: Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
Study NCT01205906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior group therapy for tinnitus
Description: Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
Study NCT01205906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet discussion forum
Description: Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
Study NCT01684683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo(for Theophylline)
Description: Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
Study NCT00971425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemrix (GSK investigational influenza GSK2340272A vaccine)
Description: 2 doses intramuscular injections
Study NCT00971425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluarix™
Description: 1 dose intramuscular injection
Study NCT00971425 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 1 dose intramuscular injection
Study NCT03379480 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga arm
Description: Yoga module developed for patients with Schizophrenia
Study NCT03573440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mindful education on eating
Description: Mindful eating education material: mindful eating handout by move.va.gov. It includes topics such as: observe your body, do not judge yourself, notice your reaction to food and savor your food.
Study NCT04101448 — intervention group
Intervention type: OTHER
Intervention: prevalence
Description: percentage of bronchectasis in COPD and its effect as prognostic measure
Study NCT01297712 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Latest generation colonoscopy as diagnostic instrument
Description: this endoscope is used as compared to an older generations cope (classic line) currently in use
Study NCT00686933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-089
Description: Subjects will take up to 80 mg daily for 24 months
Study NCT02383498 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
Study NCT02383498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301 Vaccine (Yeast- Brachyury)
Description: GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
Study NCT01207388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion
Study NCT00187889 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eplerenone
Description: Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
Study NCT00187889 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo or sugar pill
Description: Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
Study NCT06118164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pursing- lip breathing combined with aerobic walking exercise
Description: pursing- lip breathing combined with aerobic walking exercise
Study NCT06118164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: pursing- lip breathing
Description: pursing- lip breathing
Study NCT06118164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: aerobic walking exercise
Description: aerobic walking exercise
Study NCT03278652 — intervention group
Intervention type: OTHER
Intervention: Consumption of drugs for analgesic use
Description: * Regular assessment of pain~* Drug data will be collected (name, dosage, route of administration, time of delivery)
Study NCT03703687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gratitude intervention
Description: The intervention will be proposed to both the patient and the caregiver and consists of two steps: the gratitude letter and the gratitude visit. In the gratitude letter, the individual writes about his feelings of gratitude through a letter, based on a written instruction. The gratitude visit consists of an extension of the gratitude letter where the writer of the letter (i) either personally reads the letter to the beneficent or (ii) gives it to him and asks him to read it in his presence or later in his absence.
Study NCT03661450 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical Decision-Support System
Description: Patient Data is evaluated by a Clinical Decision-Support System searching for age-adapted pediatric SIRS-criteria, aiming for a high sensitivity and specificity
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (100/31.25/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily \[QD\] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (100/62.5/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (200/31.25/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI (200/62.5/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI (100/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FF/VI (200/25) mcg
Description: Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/salmeterol (FSC)
Description: Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
Study NCT02924688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol/salbutamol
Description: This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
Study NCT02924688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
Study NCT00727948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg tablets, once daily for 45 days
Study NCT02808949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapivirine
Description: Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
Study NCT01703884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASAQ
Description: In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
Study NCT02524717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56021927
Description: Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
Study NCT01083810 — intervention group
Intervention type: DRUG
Intervention: Lopinavir/Ritonavir (Kaletra)
Description: 3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
Study NCT03880435 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalobarrier® gel endo
Description: Intra-uterine application of 10ml sterile gel containing 30mg APC. It will be administered once, peroperatively immediate after the complete hysteroscopic removal of the polyp, myoma, adhesion, uterine septum or retained products of conception
Study NCT02257294 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
Study NCT02257294 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
Study NCT02257294 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
Study NCT01969448 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inframammary Fold Incision or Lateral Radial Incision
Study NCT01969448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral Radial Incision
Study NCT01969448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inframammary Fold Incision
Study NCT01969448 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser-assisted fluorescence angiography
Study NCT01969448 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Laser-assisted fluorescence angiography
Study NCT01969448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indocyanine Green
Study NCT02924688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ELLIPTA DPI
Description: The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
Study NCT02924688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS DPI
Description: The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
Study NCT02924688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DISKUS DPI
Description: The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
Study NCT02924688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: METERED-DOSE INHALER (MDI)
Description: Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
Study NCT02924688 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: METERED-DOSE INHALER (MDI)
Description: Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
Study NCT00648141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule once daily for 12 weeks
Study NCT00648141 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg oral capsule twice daily for 12 weeks
Study NCT00648141 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 75 mg oral capsule twice daily for 12 weeks
Study NCT02877849 — intervention group
Intervention type: DEVICE
Intervention: MRI: Brain Imaging data collection
Description: This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
Study NCT03768895 — intervention group
Intervention type: RADIATION
Intervention: MRI
Description: The technique used was coronal and axial T1 and T2\*WI sequences of the pelvis and femurs.~The MRI machine used is a HITACHI AIRIS-II1 model, with permanent vertical magnetic field of 0.3 Tesla, and the used sequences areT1, T2\*WI.
Study NCT02293993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Study NCT00979017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin, by intravenous infusion, 10 mg/kg every 14 days
Study NCT00979017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral temozolomide at 200 mg/m2 daily for 5 days
Study NCT00979017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
Study NCT02362542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
Study NCT01725256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AIR001 (sodium nitrite inhalation solution)
Description: Dose arms specify dose loaded into the I-neb AAD System nebulizer
Study NCT00120289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release niacin
Description: 2,000 mg/day or 1,500 mg/day if higher dose not tolerated
Study NCT00120289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
Study NCT00120289 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
Study NCT01001858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diagnosis and monitoring of OSA patients
Description: The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
Study NCT02521909 — intervention group
Intervention type: DEVICE
Intervention: ProMark (Tooth Extraction for Assessment of Different Apex Locators)
Description: The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.